Get the Stockscreener App
36.27
3.39%
1.19
Pre-market:
36.58
0.31
+0.85%
Veracyte Inc stock is traded at $36.27, with a volume of 931.47K.
It is up +3.39% in the last 24 hours and up +0.47% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$35.08
Open:
$35.22
24h Volume:
931.47K
Relative Volume:
1.14
Market Cap:
$2.87B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-48.36
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
+1.54%
1M Performance:
+0.47%
6M Performance:
+15.07%
1Y Performance:
+6.33%
1-Day Range:
$35.00
$36.56
1-Week Range:
$34.21
$39.89
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
36.27 | 2.77B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. $VCYT Shares Acquired by ARK Investment Management LLC - MarketBeat
Affiliate to sell 6,658 Restricted Stock Units — VCYT (NASDAQ: VCYT) - Stock Titan
[144] VERACYTE, INC. SEC Filing - Stock Titan
Marc Stapley (NASDAQ: VCYT) reports sale of 15,000 shares for $1.92M - Stock Titan
Veracyte (NASDAQ: VCYT) VP has 3,006 shares withheld for taxes - Stock Titan
Veracyte (VCYT) CFO reports 7,234-share tax withholding, not a sale - Stock Titan
[Form 4] VERACYTE, INC. Insider Trading Activity - Stock Titan
Veracyte (VCYT) exec sells 13,425 shares, 117,346 remain - Stock Titan
Veracyte (VCYT) CEO has 19,455 shares withheld to cover taxes - Stock Titan
Segall Bryant & Hamill LLC Has $18.31 Million Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Champlain Investment Partners LLC Makes New $40.06 Million Investment in Veracyte, Inc. $VCYT - MarketBeat
VCYT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Veracyte, Inc. (VCYT) Stock Analysis: Uncovering A Promising 34.96% Upside For Investors - DirectorsTalk Interviews
William Blair Investment Management LLC Buys New Stake in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook - Yahoo Finance
JPMorgan Chase & Co. Has $17.81 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Cathie Wood’s ARK sells Veracyte stock, buys MercadoLibre - Investing.com India
Veracyte Inc. Signals Durable Growth in Earnings Call - TipRanks
Veracyte, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-03-02 - Seeking Alpha
Veracyte (VCYT) CCO John Leite receives PSU shares, withholds stock for taxes - Stock Titan
Veracyte (VCYT) CEO reports PSU vesting and tax withholding share disposition - Stock Titan
Veracyte (VCYT) CFO granted shares as PSUs vest, with tax shares withheld - Stock Titan
Veracyte (NASDAQ: VCYT) officer gets PSU vesting, withholds shares - Stock Titan
Veracyte (VCYT) SVP awarded 50,999 shares; some withheld for taxes - Stock Titan
How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors - simplywall.st
Vanguard Group Inc. Raises Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Veracyte Stock Soars 8.48%, Hits Intraday High of $39.89 - Markets Mojo
Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript - Insider Monkey
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Artisan Partners Limited Partnership Acquires 1,048,692 Shares of Veracyte, Inc. $VCYT - MarketBeat
VCYT Gains Analyst Support: Needham Raises Price Target | VCYT S - GuruFocus
Veracyte Presents 15 Studies on Decipher Cancer Tests at ASCO GU Symposium - Clinical Lab Products
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises - Yahoo Finance
Veracyte (NASDAQ:VCYT) Shares Gap Up on Analyst Upgrade - MarketBeat
Veracyte (NASDAQ:VCYT) Price Target Raised to $48.00 - MarketBeat
Veracyte stock price target raised to $48 by Needham on growth - Investing.com Australia
Veracyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Veracyte Q4 Earnings Call Highlights - MarketBeat
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience - Sahm
Veracyte Inc earnings beat by $0.14, revenue topped estimates - Investing.com Australia
Veracyte Inc (VCYT) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Veracyte Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Veracyte(VCYT.US) Q4 2025 Earnings Conference - 富途牛牛
Veracyte Q4 2025 slides: 19% revenue growth, profitability soars By Investing.com - Investing.com Nigeria
Earnings call transcript: Veracyte Inc. beats Q4 2025 forecasts, shares edge up - Investing.com Nigeria
Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Earnings call transcript: Veracyte Inc. beats Q4 2025 forecasts, shares edge up By Investing.com - Investing.com South Africa
Veracyte (VCYT) Exceeds Q4 Revenue Expectations and Gears Up for 2026 Launches - GuruFocus
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):